JV001 / Juvensis Therap - LARVOL DELTA

MERCURY-DCM: Myocardial Telomere Recapping Study for Dilated Cardiomyopathy (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Shanghai East Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2024 ➔ Jul 2025

Enrollment closed • Trial completion date • Trial primary completion date • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • CXCL8 • IFNA1 • IFNG • IL10 • IL17A • IL1B • IL2 • IL4 • IL5 • IL6 • ST2 • TNFA

Design of a Pan Heart Failure Gene Therapy by Targeting Telomere-p53 Axis (AHA 2023) - P1 | "These preclinical studies demonstrate considerable potential for the first pan-HF single-dose gene therapy that can reverse cardiac function and prevent myocardial remodeling which would be invaluable clinically and an Investigator Initiated Trial (IIT) (NCT05837143) was launched in April 2023."

Gene therapy • Cardiovascular • Congestive Heart Failure • Fibrosis • Gene Therapies • Heart Failure • Immunology • Metabolic Disorders